Remove Download Remove Immunity Remove Immunization
article thumbnail

FDA expands AVTOZMA IV approval to include cytokine release syndrome

Pharma Times

CRS is a potentially life-threatening condition triggered by excessive immune activation. Celltrion emphasised the significance of the milestone in advancing treatment options for immune-related conditions. It leads to a rapid release of cytokines into the bloodstream, causing inflammation and damage to healthy tissues.

article thumbnail

Osivax publishes phase 2a results supporting dual flu vaccine approach

Pharma Times

The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Flu Vaccines Are a Go

Pharmacy Times

That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025. Editor's Footnote In May 2025, Secretary Robert F. Kennedy Jr.

article thumbnail

From Pharmacy Counters to Classrooms: Building Confidence in Back-to-School Vaccinations

Pharmacy Times

Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates. Collaborative programs between public health departments, schools, and pharmacies aim to streamline vaccine access and improve immunization coverage.

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.

article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

The legislation also supports the use of mobile manufacturing units, offering close-to-home treatment for patients too unwell to travel, or whose weakened immune systems mean hospital visits carry extra risk. Please check your inbox to download the Whitepaper. You will receive an email shortly.

article thumbnail

Pharmacists Bridge the Gaps in Care Transitions

Pharmacy Times

Centers for Medicare & Medicaid Services. Updated September 10, 2024. Accessed July 7, 2025.[link]